Trial Profile
Expanded Access to ABBV-8E12
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 21 Aug 2019
Price :
$35
*
At a glance
- Drugs Tilavonemab (Primary)
- Indications Tauopathies
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
- 16 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2018 New trial record